BOSTON, June 12, 2006 — CoGenesys Inc. announced today the completion of a $55 million Series A financing, which will be used to advance the company's pipeline of product candidates entering clinical-stage development. The financing was led by New Enterprise Associates with additional investments by OrbiMed Advisors and Red Abbey Venture Partners and a significant equity participation by Human Genome Sciences Inc. CoGenesys is advancing a broad pipeline of improved, long-acting biopharmaceuticals developed to address unmet medical needs across a broad spectrum of therapeutic areas.
Goodwin Procter LLP attorneys Mitchell Bloom and Danielle Lauzon represented the investors in this transaction.